| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Protein Phosphatase 2A (PP2A) is a primary target, and SH-BC-893 acts as an activator. It is a synthetic sphingolipid analog that activates PP2A, a serine/threonine phosphatase. By activating PP2A, it disrupts oncogenic signaling pathways and nutrient-sensing mechanisms (e.g., mTOR). It also targets mitochondrial and lysosomal functions directly.
|
|---|---|
| ln Vitro |
By inhibiting lysosomal trafficking events and downregulating cell surface nutrient transporters, SH-BC-893 starves cancer cells [1]. By interfering with intracellular trafficking, SH-BC-893 (5 μM; 3 hours) stops the fragmentation of the mitochondrial network caused by ceramides [2]. The antioxidant SH-BC-893 (8.935 nM; 3 hours) guards against mitochondrial dysfunction brought on by ceramides [2].
In vitro, SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. It modulates mitochondrial function, protecting from ceramide-induced mitochondrial dysfunction, which is often associated with cell death and metabolic disease. It promotes the internalization of nutrient transporters from the cell surface, thereby disrupting lysosomal trafficking and reducing the cellular uptake of glucose and amino acids, leading to growth arrest in cancer cells. |
| ln Vivo |
Oral SH-BC-893 (120 mg/kg; single dosage) corrects diet-induced obesity and its metabolic aftereffects while potently and rapidly blocking ceramide-induced mitochondrial dysfunction[1].
In vivo, SH-BC-893 is orally active and has been shown to correct diet-induced obesity and reduce tumor growth. By limiting nutrient uptake and improving mitochondrial function, it suppresses tumor growth in model systems and prevents the metabolic dysfunction associated with high-fat diets. It is also utilized in research for cancer and obesity, demonstrating broad therapeutic potential in preclinical models. |
| Enzyme Assay |
For non-cellular assays, Protein Phosphatase 2A (PP2A) activity is measured. Purified PP2A enzyme is incubated with a fluorogenic phosphopeptide substrate (e.g., RRA(pT)VA). SH-BC-893 is added at increasing concentrations. The release of phosphate is measured via fluorescence intensity (Ex 360/Em 460) to calculate the EC50 for PP2A activation.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: p53 flox/flox MEFs Tested Concentrations: 5 μM Incubation Duration: 3 h Experimental Results: Blocked palmitate-induced recruitment of DRP1 to mitochondria without affecting DRP1 protein levels. Immunofluorescence[1] Cell Types: p53 flox/ flox MEFs Tested Concentrations: 5 μM Incubation Duration: 3 h Experimental Results: Blocked palmitate-induced recruitment of DRP1 to mitochondria. For cellular assays, cancer cells or primary cells are treated with SH-BC-893 (0.1-10 uM) for 6-24 hours. Nutrient uptake is measured using fluorescently labeled analogs (e.g., 2-NBDG for glucose, and dansyl-labeled amino acids). Lysosomal function is assessed by measuring the activity of cathepsins or by visualizing lysosomal pH using LysoTracker dyes. Mitochondrial function is measured using the Seahorse XF Analyzer to determine oxygen consumption rate (OCR). |
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice (Male)[1]
Doses: 120 mg/kg Route of Administration: Oral; single Experimental Results: Blocked palmitate- and ceramide-induced mitochondrial fission, preserved mitochondrial function, and prevented ER stress. Normalized mitochondrial morphology in the livers and brains of HFD-fed mice, improved mitochondrial function in white adipose tissue, and corrected aberrant plasma leptin and adiponectin levels. Restored normal body weight, glucose disposal, and hepatic lipid levels in mice consuming a HFD. For in vivo efficacy studies, SH-BC-893 is formulated in a vehicle such as 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline for oral administration. For tumor studies, it is administered to mice bearing subcutaneous xenografts (e.g., colorectal or pancreatic cancer). For metabolic studies, it is given to mice maintained on a high-fat diet (HFD). Body weight, food intake, and glucose tolerance (GTT) are measured. Tumors and metabolic tissues (liver, adipose) are harvested for histology and Western blot to assess cell proliferation (Ki-67) and mTOR signaling. |
| ADME/Pharmacokinetics |
SH-BC-893 is a small molecule with a molecular weight of 325.92 g/mol and a molecular formula of C19H32ClNO. It is orally bioavailable, a key feature that distinguishes it from many other sphingolipid analogs. Detailed PK parameters (e.g., half-life, Cmax, AUC) are likely available in preclinical literature for the specific mouse strains used. It is typically stored as a solid at -20degC and is soluble in DMSO and ethanol.
|
| Toxicity/Toxicokinetics |
SH-BC-893 has been investigated in preclinical studies and is generally well-tolerated at therapeutic doses. Reports indicate "no observable toxicity" at doses that are effective in correcting obesity and suppressing tumor growth. However, comprehensive acute and chronic toxicology datasets required for IND filing are not detailed in the provided supplier literature. As with all research chemicals, standard precautions should be taken.
|
| References |
|
| Additional Infomation |
SH-BC-893 is a research-grade chemical and is not an FDA-approved drug. It is a synthetic analog of sphingolipids, which are natural bioactive lipids. Its unique triple mechanism of action (PP2A activation, mitochondrial protection, and nutrient transport inhibition) makes it a valuable probe for dissecting the interplay between cell signaling and metabolism. It is being developed by the lab of Dr. Levi Garraway.
|
| Molecular Formula |
C19H32CLNO
|
|---|---|
| Molecular Weight |
325.916484832764
|
| Exact Mass |
325.217
|
| CAS # |
1841409-92-4
|
| PubChem CID |
155512882
|
| Appearance |
Colorless to light yellow liquid
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
260
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCC1=CC=C(C=C1)[C@H]2CCN[C@@H]2CO.Cl
|
| InChi Key |
QJRPLIVTEDTSKX-STYNFMPRSA-N
|
| InChi Code |
InChI=1S/C19H31NO.ClH/c1-2-3-4-5-6-7-8-16-9-11-17(12-10-16)18-13-14-20-19(18)15-21;/h9-12,18-21H,2-8,13-15H2,1H3;1H/t18-,19-;/m1./s1
|
| Chemical Name |
[(2S,3R)-3-(4-octylphenyl)pyrrolidin-2-yl]methanol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0682 mL | 15.3412 mL | 30.6824 mL | |
| 5 mM | 0.6136 mL | 3.0682 mL | 6.1365 mL | |
| 10 mM | 0.3068 mL | 1.5341 mL | 3.0682 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
